STAG2 Expression in 97 MDS Patients with Karyotype and Progression Data

Comprising immunohistochemistry and cytogenetic analysis results for 97 myelodysplastic neoplasm (MDS) patients and 20 controls. It includes STAG2 protein expression levels, karyotype classifications, and patient evolution to acute myeloid leukemia (AML). The data was generated by Beatriz Ferreira da Silva to investigate STAG2 as a biomarker associated with aneuploidy and disease progression.

Use Cases

• Analyze the association between reduced STAG2 expression and abnormal karyotypes, including structural alterations and aneuploidies.
• Investigate the correlation of STAG2 expression levels with specific cytogenetic abnormalities like complex karyotypes and trisomy of chromosome 8.
• Assess the potential of STAG2 expression as a prognostic biomarker by examining its link to patient evolution to AML.
• Perform bioinformatic enrichment analysis on STAG2 interactors related to pathways like mitotic regulation and chromatin control.

Strengths

• Includes data from 97 MDS patients and 20 controls, providing a clinical cohort for analysis.
• Contains detailed cytogenetic classifications, with abnormal karyotypes found in 41% (40/97) of patients.
• Reports specific associations, such as reduced STAG2 expression in 86% of patients with both structural and aneuploidy alterations.

Limitations

• Small sample size of 97 patients limits statistical power for subgroup analyses.
• Data is presented in a DOCX file format, which is not ideal for direct computational analysis and may require manual extraction.
• The dataset scope is limited to the specific study's patient cohort and methodology, with no clear indication of temporal coverage.

Provenance

Source

Beatriz Ferreira da Silva via figshare.

Collection Method

STAG2 expression analyzed by immunohistochemistry on bone marrow biopsies; cytogenetic analysis performed by G-banding and FISH.

Freshness

Last updated in March 2026.